プログラム

Final Agenda

Monday, May 7

8:00 am Workshop Registration and Morning Coffee

9:00 am - 12:00 pm Pre-Conference Workshop*: The Key Skills of the Alliance Manager: Models, Tools and Frameworks for Maximum Impact

All Alliance Managers want to have impact, and most have the natural core skills to do so. That said, to have true impact, Alliance Managers need to move beyond their natural ideas and inclinations, and get ever more systematic and clear about their approach, and get better at applying specific models and tools to their role. In this highly interactive, experiential and case study-based workshop, Alliance Managers will learn about, discuss and practice using an Alliance Manager toolkit that, coming out of the session, will enable them to both immediately and continually over time enhance their ability to make a real and positive impact on their alliances and those alliances' ability to execute toward their goals.

Instructors: 

Adam_KornetskyAdam Kornetsky, Senior Consultant, Vantage Partners LLC


Electra_HuiElectra Hui, Senior Consultant, Vantage Partners LLC


*Separate registration required

12:00 pm Main Conference Registration

1:10 Chairperson's Opening Remarks and Welcome

Micah Lieberman, Executive Director, Conferences, BioPharmaceutical Strategy Series, Cambridge Healthtech Institute (CHI)

アイスブレーキング

1:15 Opening Ice Breaker and State of Alliance Management in Industry: Progress and Challenges

Dana_HughesDana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

As we gather for another year of discussions and the sharing of stories from our organizations, are we making progress as a community? This short presentation will set the stage for the conference and prepare everyone for a deeper interactive discussion at the end of the day in the form of the "Big Pharma-Biotech Back-and-Forth: Tell Me What's Wrong, and How I Can Help!".

有効な戦略的提携管理を導入し提携能力を構築するための第1歩

1:35 Shaping a New Company Capability in Alliance Leadership

Mark_CoflinMark Coflin, Head, Alliance Management, Corporate Planning & Program Management, Shire

Shaping a new company with an innovative approach to Alliance Management leadership is an exciting opportunity! Shire is the leading rare disease-focused biotech focused on rare disease targeting highly specialized conditions. This presentation will discuss key learnings on designing and building the organizational Alliance Management capability, championing change and overcoming obstacles in the journey. This presentation will share the vision of success, the roadmap, and practical tips for everyone.

2:20 People in Alliance Management

Lena_FrankLena Frank, Executive Director, Program & Alliance Management, Oncology Business Group, Eisai Inc.

Whether you are considering hiring your first alliance manager, developing an alliance management group or looking to transform your group, there are a number of factors to consider: 1. Should alliance management be a standalone function? 2. Is there a difference between alliance management and project management? 3. What skill sets and capabilities are needed in alliance management? 4. How do you find your next alliance manager?

2:50 Networking Refreshment Break with Exhibit Viewing

提携による可能性を高め、文化を醸成させるための戦略

3:55 Chairperson's Remarks

Mark Coflin, Head, Alliance Management, Corporate Planning & Program Management, Shire

4:00 Principle-Centered Alliance Management

Michael_KennedyMichael Kennedy, PhD, MBA, Director, Alliance Management, Business Development & Licensing, Bayer HealthCare

Developing a corporate partnering capability and culture takes time and goes through many stages, from establishing the role of alliance management through ensuring that alliance-involved individuals are equipped with the skills and competencies required to manage complex collaborative relationships. Few endeavors go further toward achieving these objectives than aligning leaders, teams, and organizations around a carefully defined set of partnering principles.  

4:30 Evolving Alliance Management for the Partnering Everywhere World

Jan_TwomblyJan Twombly, CSAP, President, The Rhythm of Business

The structure, size, scope, and responsibilities of alliance management departments are evolving to address the increasing amount of partnering activity everywhere throughout the business. Based on a recently completed research study covering companies of varying sizes and maturity of alliance management practices, data will be presented to highlight: 1) How the alliance management function is evolving to meet the needs of their internal stakeholders as well as partners; 2) The challenges encountered and how they are being addressed.

グループ討論: BIG PHARMA-BIOTECH BACK-AND-FORTH

5:00 Big Pharma-Biotech Back-and-Forth: Tell Me What's Wrong, and How I Can Help!

Dana_HughesDana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

Join a frank and open discussion involving all conference participants on the real issues surrounding managing partnerships between large and small companies. Often, each side is unaware of how to improve to better align with their partner. This session provides attendees with insights into critical pain-points from the perspective of each side, while offering best practices to alleviate common issues, and real-time problem-solving for more difficult issues.

5:45 Welcome Reception with Exhibit Viewing (Sponsorship Opportunity Available)  

7:00 Close of Day

Tuesday, May 8

7:30 am Registration Open

8:00 Interactive Breakout Discussion Groups and Speed Networking with Continental Breakfast

Grab a cup of coffee and delve deeper into some of the overarching concerns facing alliances today. These are moderated roundtables with brainstorming and interactive problem-solving, allowing conference participants from diverse backgrounds to have frank discussion while exchanging ideas, experiences, and developing future collaborations around a focused topic.

Table 1: Alliance Management at the Forefront of Deal-Making

One of the principal roles of an alliance manager is to manage the collaboration based on an agreed-upon contract. Ahead of the contract signing, during the negotiation process, alliance managers are in a unique position to provide input based on the management of past deals. This group will explore ways in which Alliance Management can get involved earlier in the deal-making process, transferring the knowledge and experience of managing other partnerships.

  • At what point should Alliance Management get involved in the deal-making process?
  • What contributions can an alliance manager make to the negotiation process?
  • How would a partner perceive Alliance Management at the table? What message would that deliver about your company's approach to partnership?
  • What steps are required to gain alignment in your own organization about the role of Alliance Management in the deal-making process?

Table 2: Alliance Launch

Organizations commit significant resources to alliance deals that are central components of the organization's long-term strategy. Too often, however, such deals get "thrown over the fence" from those who identify the asset, to those responsible for negotiating and closing the deal, to those finally responsible for managing the working relationship with the partner organization. This group will explore some of the challenges and some best practices for launching an alliance for success.

  • How, if at all, does your organization employ a systematic approach to launch alliances?
  • What are the initial challenges, necessities and opportunities during an alliance launch?

Table 3: Alliance Management & Project Management - Managing the Divide

Alliance Management (AM) and Project/Program Management (PM) can be similar enough that many companies struggle to manage the divide between the functions, or debate if the two functions need to be separate. This roundtable will tackle the issues of whether alliance management and project management should be treated separately or as a combined function, including the following topics:

  • Benefits of separate functions versus single function
  • Assigning roles and responsibilities
  • Ensuring responsibilities of both functions are managed adequately

Table 4: Introducing Alliance Management to a Growing Biotech Company

A larger percentage of alliance deals in the life sciences space involve a Big Pharma - Biotech partnership. This group will discuss the key aspects to consider before introducing alliance management to biotech companies.

  • What types of alliances should innovative enterprises form?
  • Which alliance management skills and tools do companies need to possess?
  • How can organizations develop a culture of open innovation?
  • What are the ways to create value and share it among stakeholders involved?
  • How do you get CEO & senior management engagement?
  • What questions should senior management ask as they implement policies, processes, and SOPs that will apply to (and possibly conflict with) partners?

Table 5: A Review of Best Practices for Collaborations between Pharmaceutical Companies and Companion Diagnostic Providers

At some point, most pharmaceutical companies look for a diagnostic partner. This group will discuss issues surrounding selecting a partner and avoiding challenges in managing these types of partnerships.

  • What factors do you consider in selection of a companion diagnostics partner?
  • What are the key milestones and associated decision points moving forward in diagnostic development?
  • How long does it take to complete an agreement with a CoDx partner?
  • Is it a fee for service, pay as you go or broader alliance?

新たなフロンティア:技術ベースのパートナーシップ

9:25 Chairperson's Remarks

Micah Lieberman, Executive Director, Conferences, BioPharmaceutical Strategy Series, Cambridge Healthtech Institute (CHI)

9:30 Case Study: Can Gaming Play Nicely with Pharma

Joe_KoziakJoseph Koziak, CEO, Executive, Amblyotech Inc.

Amblyotech is a life sciences company that has partnered with Ubisoft, a gaming company. The collaboration created the Amblyotab, a novel, patented medical device to treat Amblyopia, a condition that has remained effectively untreated for over 300 years.

 

10:00 KEYNOTE PRESENTATION: Cracking the Code on Technology-Based Partnerships

Stuart_KlimanStuart Kliman, JD, Partner, Vantage Partners

Pharma/biotech firms are increasingly pursuing partnerships with technology firms, and other non-traditional partners, to create differentiated value propositions, broaden their customer base, and enable new financial models. Success in these relationships can be difficult given the significant differences between pharma and tech business models. This presentation will focus on how your organization can clarify its purpose for pursuing alliances with technology companies, ensure that these alliances are supportive of your overall business strategy, think holistically about how these new types of alliances fit within your existing ecosystem of relationships, and identify, evaluate, and select potential partners to meet your specific needs.

10:45 Networking Coffee Break with Exhibit Viewing

選ばれるパートナー:Pfizer, Bayer, SANOFI, GSK, AbbVie, Astrazeneca, CELGENE, Boehringer の新たなイニシアチブ検証

11:30 The Pfizer Model of Alliance Management

Dana_HughesDana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

At Pfizer, we strongly differentiate between the alliance function, a very small core of professionals at the center, and alliance capability, which we aim to strengthen at multiple levels throughout the company. Our priority is to build on the existing alliance capability within our businesses, while maintaining a highly leveraged corporate alliance team to ensure success of our most important deals. Pfizer BD sees this balance as critical to the success of our deals, a match to expectations in our potential partner set and an appropriate match to Pfizer's strengths. Recognizing that many peers see significant value in a more functional approach to alliance support, with larger central corporate alliance teams, we intend to display our model - as well as discuss its advantages and disadvantages. All participants should see how they can plug easily into Pfizer's partnering capability.

12:00 pm Alliance Capability - How to Develop a Corporate Capability and Explore the Upsides for the Organization

Karen_DentonKaren Denton, Director, Alliance Management, Bayer Health Care Pharmaceuticals

This presentation will detail a recent initiative at Bayer to develop and implement an over-arching alliance management competency model and associated developmental pathways for both alliance managers and those working on alliances.


12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

2:00 The Evolving Role of Alliance Management in the Pharmaceutical Industry: How to Contribute to the Mission of Bringing Innovative Medicines to Patients Despite Organizational Changes

Varavani_DwarkiVaravani Dwarki, PhD, Vice President, Alliance Management Business Partner, General Medicines and Emerging Markets (GEM) and Consumer Health Care (CHC) Business Units; Head, Alliance Management Center of Expertise, Sanofi

During this presentation, I will provide a provide a perspective on how the AM role has evolved in bringing value to the stakeholders, and how we as a AM community can build on this to elevate our profession and visibility.

2:30 Establishing Option-Based Deals that Work for Both Parties

Anna_MaroneyAnna Maroney, PhD, Vice President, Head Alliance Management, Corporate Strategy Office, AbbVie

At AbbVie, we have an integrated approach to business development where Alliance Management is engaged at completion of diligence to deal execution. As part of our corporate responsibility, Alliance Management is best positioned to understand and help the organization become "partners of choice". This presentation will share insights from an internal contract initiative to identify areas of consideration in partnerships constructed via option-based deals.

3:00 Role of Alliance Management in Mergers, Acquisitions & Divestments at GSK

Steven_PessagnoSteven Pessagno, Alliance Director and Head of CoE Operations, Alliance Management, Worldwide Business Development, GlaxoSmithKline

Across the life sciences industry, we spend billions each year on mergers, acquisitions and divestments of all types in order to ensure R&D portfolios are shaped so that the right companies are developing the right medicines for patients given company strategies and competencies. Ultimately, we hope that patient benefits from innovative medicines involved in MA&D transactions are optimized and shareholder values of the companies are increased. We all have our own stories to tell about how MA&D transactions are structured, how the work is carried out, and how value is delivered as a result. The role of Alliance Management in MA&D transactions continues to evolve at GSK and, presumably, the industry - though the AM role tends to vary from deal to deal. Based on the current state of play, how does the profession think AM should be involved in MA&D for optimal impact?

INTERACTIVE DISCUSION: How Alliance Management Can Make MA&D Work Less Maddening - and Optimize Value

Steven Pessagno, Alliance Director and Head of CoE Operations, Alliance Management, Worldwide Business Development, GlaxoSmithKline

Mergers, acquisitions & divestments tend to be viewed and managed as time-limited projects within companies, yet they are business alliances entered into for a certain period in order to accomplish specific strategic goals and deliver a targeted amount of value. Is the role of Alliance Management in MA&D where it should be across the industry?

  • How does Alliance Management tend to be involved in MA&D transactions at your company, and what are the determining drivers?
  • In what way(s) would you like to see the profession of AM think about our role in MA&D differently; likewise, how do we want our companies to view and employ AM in MA&D transactions?
  • What are best practices and lessons learned you can share from an AM perspective in MA&D work you've led or been involved with?

4:00 Networking Refreshment Break with Exhibit Viewing

4:30 Alliance Management at AstraZeneca

Joe_McCulloughJoe McCullough, Alliance Director, AstraZeneca


5:00 Celgene's Alliance Management - Building Capabilities with Diverse Relationships

Krishnan_ViswanadhanKrishnan Viswanadhan, PharmD, MBA, Vice President,, Business Development & Global Alliances, Celgene Corporation

This presentation will provide an overview of Celgene's story, including details on its driving culture, core focus and pipeline, including the alliance management history. Discussion will focus on how we build and manage diverse partnerships and our approach to managing the portfolio of alliances, as well as share what's next for Celgene's partnerships.

5:30 Working Together for Better Health

Mark_RalphMark Ralph, Global Head, Contracts and Alliance Management, Boehringer Ingelheim

Boehringer Ingelheim seeks to establish mutually beneficial collaborations with academic, biotechnology and pharmaceutical partners in areas of strategic interest. We see these partnerships as being critical to the success of our drug discovery efforts and our pursuit of better therapeutics for the patients we serve. This presentation will give an overview of Boehringer Ingelheim, our partnering philosophy and strategic interests, in addition to detailing our approach to alliance management and how we seek to drive collaborations to have mutually beneficial outcomes.

6:00 Close of Day

Wednesday, May 9

8:00 am Morning Coffee

現状のパートナーシップと提携管理のケーススタディ

8:25 Chairperson's Opening Remarks

Speaker to be Announced


8:30 KEYNOTE CO-PRESENTATION AND CASE STUDY: Importance of Alliance Joint-Team Membership Longevity

Dana_HammillDana Hammill, MS, MBA, Director, Business Development and Alliances, Center for Cellular Immunotherapies, University of Pennsylvania


Simon_BatemanSimon Bateman, PhD, Executive Director, Global Strategic Alliance Management, Novartis Oncology

During the pre-launch and launch phases of an alliance, the key team players come together and learn how to best work together for mutual achievement of goals. Charters and joint team meetings are established, as well as best practices for meeting execution and communication. As months and years go by, programs, projects, and individuals come and go. This presentation will discuss examples of alliance turnover, how turnover can positively or negatively impact an alliance, and measures that can be taken to ensure that turnover has little impact on the alliance relationships, goals, and achievements.

9:15 The Three Laws of Success in Alliance Strategy

Ben_Gomes-CasseresBen Gomes-Casseres, Professor, International Business, Director, Asper Center for Global Entrepreneurship, Brandeis University; Author of REMIX STRATEGY

When your business depends on alliances, failure is not an option. You need to follow three rules to succeed: (1) target joint value; (2) govern collaboration effectively; and (3) share value fairly. These rules are based on Ben's 30 years of work with companies in pharma and other industries. This interactive session will explore what the three rules mean for you.

 

10:00 Networking Coffee Break with Exhibit Viewing

産業界、学術界、患者支援団体のパートナーシップ管理

10:30 Optimizing Academic-Industry Partnerships and the Role of Alliance Management

Joy_DickerJoy Dicker, Director, Alliance Management, Mount Sinai Innovation Partners, Mount Sinai Health System

Pharmaceutical and Biotechnology companies are increasingly looking toward Academia for research programs that can turn into new life-saving therapeutics. However, Academic Research organizations are different from Commercial organizations which presents a unique challenge for Alliance Managers.

11:00 Alternative Ways of Working with Academics

Christine Jost, PhD, Director, Alliance Management, R&D Strategy and External Innovation, Sanofi

Sanofi has embarked on a new collaborative program, the Sanofi iAwards. This collaboration involves seven academic partners. The goal is to increase connectivity with academics and bring more innovation to pharma. Attendees will learn more about the Sanofi iAwards and the lessons learned from managing a large multi-party academic alliance.

11:30 Improving Development and Manufacturing Alliances

Jose_OchoaJose Ochoa, Chief Business Officer & Head, Animal Health Americas, IDT Biologika Corporation

IDT Biologika offers customers access to highly integrated development and manufacturing services, including one of the most comprehensive quality control and testing programs in the industry. This presentation will highlight the execution and lessons learned from recent alliances IDT Biologika has entered into to provide an end-to-end solution for the manufacture of antibody drug conjugates and live virus filling and finishing services.

12:00 pm Industry Alliances with Advocacy: A New Era of Opportunities

Beth AselageBeth Aselage, Patient Advocacy & Alliance Development Specialist, Retrophin

Quick to be claimed, but slow in its actual implementation, the concept of 'patient-centricity' is transitioning from being an industry buzzword into a new paradigm of operational necessity and opportunity in healthcare. The importance of industry alliances with advocacy remains an overlooked capability within most organizations. Through highlighting some of the [lesser known] benefits of partnering with advocacy, and observations from a case study describing a recently formed research partnership between industry, advocacy, and the NIH, the importance of alliance managers in advocacy will become transparent to anyone trying to incorporate patients into the foundation of their organization.

12:30 Close of Conference

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。